Laboratory Corporation of America Holdings (NYSE:LH) CEO David P. King sold 132,713 shares of Laboratory Corporation of America Holdings stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $157.06, for a total transaction of $20,843,903.78. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Shares of Laboratory Corporation of America Holdings (LH) traded down 0.23% during trading on Thursday, reaching $158.11. 234,633 shares of the company were exchanged. The stock has a market capitalization of $16.10 billion, a price-to-earnings ratio of 22.14 and a beta of 0.94. Laboratory Corporation of America Holdings has a one year low of $119.51 and a one year high of $164.22. The company has a 50 day moving average price of $156.81 and a 200-day moving average price of $146.95.

Laboratory Corporation of America Holdings (NYSE:LH) last announced its quarterly earnings results on Wednesday, July 26th. The medical research company reported $2.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.40 by $0.07. Laboratory Corporation of America Holdings had a return on equity of 16.85% and a net margin of 7.57%. The business had revenue of $2.50 billion during the quarter, compared to the consensus estimate of $2.47 billion. During the same quarter last year, the firm posted $2.36 EPS. The company’s quarterly revenue was up 4.9% on a year-over-year basis. Equities analysts predict that Laboratory Corporation of America Holdings will post $9.51 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Insider Selling: Laboratory Corporation of America Holdings (LH) CEO Sells 132,713 Shares of Stock” was reported by American Banking News and is owned by of American Banking News. If you are accessing this story on another site, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/09/07/insider-selling-laboratory-corporation-of-america-holdings-lh-ceo-sells-132713-shares-of-stock.html.

A number of institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. lifted its holdings in Laboratory Corporation of America Holdings by 2.3% during the 2nd quarter. Vanguard Group Inc. now owns 10,361,891 shares of the medical research company’s stock valued at $1,597,181,000 after purchasing an additional 231,600 shares during the last quarter. BlackRock Inc. lifted its holdings in Laboratory Corporation of America Holdings by 3,602.5% during the 1st quarter. BlackRock Inc. now owns 8,074,378 shares of the medical research company’s stock valued at $1,158,430,000 after purchasing an additional 7,856,297 shares during the last quarter. State Street Corp lifted its holdings in Laboratory Corporation of America Holdings by 2.4% during the 1st quarter. State Street Corp now owns 4,639,813 shares of the medical research company’s stock valued at $665,669,000 after purchasing an additional 109,170 shares during the last quarter. Boston Partners lifted its holdings in Laboratory Corporation of America Holdings by 4.8% during the 2nd quarter. Boston Partners now owns 4,590,372 shares of the medical research company’s stock valued at $707,560,000 after purchasing an additional 210,138 shares during the last quarter. Finally, Nordea Investment Management AB lifted its holdings in Laboratory Corporation of America Holdings by 2.0% during the 2nd quarter. Nordea Investment Management AB now owns 2,696,851 shares of the medical research company’s stock valued at $415,693,000 after purchasing an additional 54,100 shares during the last quarter. 93.21% of the stock is owned by institutional investors and hedge funds.

A number of analysts have issued reports on the stock. Zacks Investment Research upgraded shares of Laboratory Corporation of America Holdings from a “sell” rating to a “hold” rating in a research note on Thursday, July 27th. Craig Hallum reiterated a “buy” rating and issued a $179.00 target price (up from $157.00) on shares of Laboratory Corporation of America Holdings in a research note on Thursday, July 27th. Barclays PLC lifted their target price on shares of Laboratory Corporation of America Holdings from $182.00 to $183.00 and gave the company an “overweight” rating in a research note on Thursday, July 27th. ValuEngine upgraded shares of Laboratory Corporation of America Holdings from a “hold” rating to a “buy” rating in a research note on Wednesday. Finally, Morgan Stanley boosted their price objective on shares of Laboratory Corporation of America Holdings from $154.00 to $166.00 and gave the stock an “overweight” rating in a research note on Thursday, August 10th. Six research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. Laboratory Corporation of America Holdings presently has a consensus rating of “Buy” and a consensus target price of $159.75.

About Laboratory Corporation of America Holdings

Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

Insider Buying and Selling by Quarter for Laboratory Corporation of America Holdings (NYSE:LH)

Receive News & Ratings for Laboratory Corporation of America Holdings Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corporation of America Holdings and related companies with MarketBeat.com's FREE daily email newsletter.